CN Patent

CN103214484A — 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶

Assigned to Because of C1-esteraseremmer-N parent corporation · Expires 2013-07-24 · 13y expired

What this patent protects

本发明提供杂芳基取代的吡咯并[2,3-b]吡啶和杂芳基取代的吡咯并[2,3-b]嘧啶，其调节两面神激酶的活性并用于治疗与两面神激酶的活性相关的疾病，包括,例如免疫-相关的疾病、皮肤病、脊髓增生性疾病、癌及其它疾病。

USPTO Abstract

本发明提供杂芳基取代的吡咯并[2,3-b]吡啶和杂芳基取代的吡咯并[2,3-b]嘧啶，其调节两面神激酶的活性并用于治疗与两面神激酶的活性相关的疾病，包括,例如免疫-相关的疾病、皮肤病、脊髓增生性疾病、癌及其它疾病。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN103214484A
Jurisdiction: CN
Classification: —
Expires: 2013-07-24
Drug substance claim: No
Drug product claim: No
Assignee: Because of C1-esteraseremmer-N parent corporation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.